Therapeutic targeting of factor D and MASP3 in complement-mediated diseases: Lessons learned from mouse studies

Area of Science:

• Immunology
• Biochemistry
• Pharmacology

Background:

• The alternative pathway (AP) of complement is implicated in numerous human diseases.
• Factor D (FD) is a key enzyme in AP activation and a therapeutic target, but its high turnover rate presents challenges.
• FD is primarily synthesized in adipose tissue, with low blood levels.

Purpose of the Study:

• To review studies on Factor D (FD) and mannose-binding lectin-associated serine protease 3 (MASP3) inhibition in mouse models.
• To discuss the implications of these findings for therapeutic targeting of FD and MASP3 in human diseases.

Main Methods:

• Review of existing literature on mouse models of FD and MASP3 inhibition.
• Analysis of the regulatory role of MASP3 in FD activation.
• Discussion of therapeutic strategies and challenges.

Main Results:

• MASP3 regulates FD activity by converting its zymogen to the mature enzyme.
• Inhibition of FD and MASP3 in mouse models shows promise for blocking AP complement activity.
• Targeting MASP3 presents a new approach to inhibit FD function.

Conclusions:

• MASP3 inhibition is a promising strategy to modulate the alternative complement pathway.
• Mouse model studies provide valuable insights for developing human therapeutics targeting FD and MASP3.
• Further research is needed to translate these findings into effective treatments for complement-mediated diseases.